AbbVie Inc. (ABBV)
Undervalued Dividend Kings: October 2024
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for potential investment. The article provides tables and charts presenting quality scores, key metrics, and fair value estimates.
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway.
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
Declining earnings haven't scared billionaire investors away from this stock.
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
These companies can lend growth and dividend returns to a long-term investor's portfolio.
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
AbbVie (ABBV) closed the most recent trading day at $195.45, moving -0.7% from the previous trading session.
AbbVie cuts 2024 profit forecast on R&D expenses
AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing $82 million in milestones, and research and development expenses related to acquisitions.
AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia
AbbVie's acquisition of Cerevel Therapeutics enhances its neuroscience pipeline with promising candidates Emraclidine and Tavapadon, expected to significantly boost revenues post-approval. Emraclidine and Tavapadon show strong clinical trial results, positioning them as potential best-in-class treatments for Schizophrenia and Parkinson's Disease, respectively. AbbVie demonstrates financial strength with rising revenues from Skyrizi and Rinvoq, supporting a bullish long-term investment thesis despite Humira's decline.
3 Top Pharma Stocks to Buy in October 2024
The pharmaceutical industry plays a crucial role in most of our everyday lives.
AbbVie: A Strong Investment Opportunity In Neurological And Oncology Breakthroughs
AbbVie presents a strong long-term investment opportunity, driven by its strategic focus on neuroscience and IBD treatments, despite challenges from Humira's decline. Tavapadon and other neuroscience drugs offer substantial growth potential, addressing unmet medical needs in Parkinson's and other neurological conditions. Skyrizi and Rinvoq are rapidly growing, offsetting Humira's revenue decline, and positioning AbbVie to capture significant market share in the expanding IBD market.
Dividend Stocks With Strong Q4 Seasonality
Entering October is the strongest period of the year for three-month returns, and shorter-term returns are also some of the best. Here we take a look at 30 dividend stocks in the S&P 500 that have been the best Q4 performers over the last ten years. 2024 has been a strong year already for high-yielding stocks, and now they have Q4 seasonality as another tailwind.
AbbVie: $200 Peak (Rating Downgrade)
AbbVie has transitioned beyond Humira's exclusivity loss, with strong growth from Skyrizi and Rinvoq, targeting $27 billion in sales by 2027. The stock has surged to $200, now trading at 16x 2025 EPS targets, making it less of a bargain. AbbVie's dividend yield is 3.1%, with a potential hike to 3.3% in October, but debt remains high at over $60 billion.
